ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
2 files

Chemical Tools for Study of Phosphohistidine: Generation of Selective τ-Phosphohistidine and π-Phosphohistidine Antibodies

preprint
submitted on 23.09.2020, 10:40 and posted on 23.09.2020, 13:21 by Mehul Makwana, Cleide Dos Santos Souza, Barry T. Pickup, Mark J. Thompson, Santosh Kumar Lomada, Yushi Feng, Thomas Wieland, Richard F. W. Jackson, Richmond MUIMO
Non-hydrolysable stable analogues of τ-pHis and π-pHis have been designed using electrostatic surface potential calculations, and subsequently synthesized. The τ-pHis and π-pHis analogues (phosphopyrazole 8 and pyridyl amino amide 13, respectively) were used as haptens to generate pHis polyclonal antibodies. Both τ-pHis and π-pHis conjugates in the form of a BSA-glutaraldehyde-τ-pHis and BSA-glutaraldehyde-π-pHis were synthesized and characterized by 31P NMR spectroscopy. Commercially available τ-pHis (SC56-2) and π-pHis (SC1-1; SC50-3) monoclonal antibodies were used to show that the BSA-G-τ-pHis and BSA-G-π-pHis conjugates could be used to assess the selectivity of pHis antibodies in a competitive ELISA. Subsequently, the selectivity of the generated pHis antibodies generated using phosphopyrazole 8 and pyridyl amino amide 13 as haptens was assessed by competitive ELISA against His, pSer, pThr, pTyr, τ-pHis and π-pHis. Antibodies generated using the phosphopyrazole 8 as a hapten were found to be selective for τ-pHis, and antibodies generated using the pyridyl amino amide 13 were found to be selective for π-pHis. Both τ- and π-pHis antibodies were shown to be effective in immunological experiments, including ELISA, western blot, and immunofluorescence. The τ-pHis antibody was also shown to be useful in the immunoprecipitation of proteins containing pHis

History

Email Address of Submitting Author

r.muimo@sheffield.ac.uk

Institution

University of Sheffield, Infection, Immunity & Cardiovascular Disease The Medical School

Country

United Kingdom

ORCID For Submitting Author

0000-0003-4242-0188

Declaration of Conflict of Interest

Two of the authors are named on relevant patents (WO/2015/033120; EU - 20160207948 and USA – US 10,053,476).

Exports